Annual CFF
$353.52 M
+$75.05 M+26.95%
December 31, 2023
Summary
- As of February 8, 2025, XENE annual cash flow from financing activities is $353.52 million, with the most recent change of +$75.05 million (+26.95%) on December 31, 2023.
- During the last 3 years, XENE annual CFF has risen by +$267.73 million (+312.05%).
- XENE annual CFF is now -21.01% below its all-time high of $447.54 million, reached on December 31, 2021.
Performance
XENE Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
$0.00
NaN%
September 30, 2024
Summary
- As of February 8, 2025, XENE quarterly cash flow from financing activities is $0.00
- XENE quarterly CFF is now -100.00% below its all-time high of $324.01 million, reached on December 31, 2023.
Performance
XENE Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFF
$324.01 M
NaN%
September 30, 2024
Summary
- As of February 8, 2025, XENE TTM cash flow from financing activities is $324.01 million
- XENE TTM CFF is now -46.57% below its all-time high of $606.48 million, reached on June 30, 2022.
Performance
XENE TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
XENE Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +26.9% | - | - |
| 3 y3 years | +312.1% | - | - |
| 5 y5 years | +216.8% | - | - |
XENE Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -21.0% | +26.9% | -100.0% | at low | -46.6% | +997.8% |
| 5 y | 5-year | -21.0% | +1184.7% | -100.0% | +100.0% | -46.6% | +1077.5% |
| alltime | all time | -21.0% | +8151.1% | -100.0% | +100.0% | -46.6% | >+9999.0% |
Xenon Pharmaceuticals Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $0.00(-100.0%) | $324.01 M(-8.3%) |
| Dec 2023 | $353.52 M(+27.0%) | $324.01 M(+998.1%) | $353.52 M(+1097.8%) |
| Sep 2023 | - | $29.51 M(>+9900.0%) | $29.51 M(-89.4%) |
| Dec 2022 | $278.47 M(-37.8%) | $6000.00(-99.1%) | $278.47 M(-53.8%) |
| Sep 2022 | - | $699.00 K(-99.7%) | $602.42 M(-0.7%) |
| Jun 2022 | - | $269.89 M(+3326.7%) | $606.48 M(+80.1%) |
| Mar 2022 | - | $7.88 M(-97.6%) | $336.70 M(-24.8%) |
| Dec 2021 | $447.54 M(+421.6%) | $323.95 M(+6708.6%) | $447.54 M(+262.0%) |
| Sep 2021 | - | $4.76 M(+4186.5%) | $123.64 M(+4.0%) |
| Jun 2021 | - | $111.00 K(-99.9%) | $118.88 M(+16.5%) |
| Mar 2021 | - | $118.72 M(>+9900.0%) | $102.05 M(+18.9%) |
| Dec 2020 | $85.80 M(+211.8%) | $45.00 K(>+9900.0%) | $85.80 M(-24.2%) |
| Sep 2020 | - | $0.00(-100.0%) | $113.18 M(-0.0%) |
| Jun 2020 | - | -$16.72 M(-116.3%) | $113.20 M(-12.9%) |
| Mar 2020 | - | $102.47 M(+273.6%) | $129.93 M(+372.2%) |
| Dec 2019 | $27.52 M(-75.3%) | $27.43 M(>+9900.0%) | $27.52 M(>+9900.0%) |
| Sep 2019 | - | $18.00 K(+63.6%) | $121.00 K(-99.8%) |
| Jun 2019 | - | $11.00 K(-81.0%) | $77.53 M(-30.5%) |
| Mar 2019 | - | $58.00 K(+70.6%) | $111.53 M(-0.1%) |
| Dec 2018 | $111.59 M | $34.00 K(-100.0%) | $111.59 M(-5.8%) |
| Sep 2018 | - | $77.43 M(+127.7%) | $118.45 M(+188.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2018 | - | $34.01 M(>+9900.0%) | $41.02 M(+484.8%) |
| Mar 2018 | - | $119.00 K(-98.3%) | $7.01 M(-0.8%) |
| Dec 2017 | $7.07 M(-70.5%) | $6.89 M(>+9900.0%) | $7.07 M(+3042.2%) |
| Sep 2017 | - | $0.00(-100.0%) | $225.00 K(-99.1%) |
| Jun 2017 | - | $3000.00(-98.3%) | $24.06 M(-0.1%) |
| Mar 2017 | - | $174.00 K(+262.5%) | $24.09 M(+0.5%) |
| Dec 2016 | $23.96 M(+8520.1%) | $48.00 K(-99.8%) | $23.96 M(+0.0%) |
| Sep 2016 | - | $23.83 M(>+9900.0%) | $23.95 M(>+9900.0%) |
| Jun 2016 | - | $38.00 K(-13.6%) | $147.00 K(-24.6%) |
| Mar 2016 | - | $44.00 K(+15.8%) | $195.00 K(-29.9%) |
| Dec 2015 | $278.00 K(-99.3%) | $38.00 K(+40.7%) | $278.00 K(-99.3%) |
| Sep 2015 | - | $27.00 K(-68.6%) | $42.66 M(+1.4%) |
| Jun 2015 | - | $86.00 K(-32.3%) | $42.06 M(+1.0%) |
| Mar 2015 | - | $127.00 K(-99.7%) | $41.64 M(+1.3%) |
| Dec 2014 | $41.12 M(-1036.6%) | $42.42 M(-7555.0%) | $41.12 M(-3275.6%) |
| Sep 2014 | - | -$569.00 K(+70.9%) | -$1.29 M(+78.4%) |
| Jun 2014 | - | -$333.00 K(-15.3%) | -$726.00 K(+84.7%) |
| Mar 2014 | - | -$393.00 K | -$393.00 K |
| Dec 2013 | -$4.39 M(<-9900.0%) | - | - |
| Dec 2012 | $0.00(-100.0%) | - | - |
| Dec 2011 | $2000.00 | - | - |
FAQ
- What is Xenon Pharmaceuticals annual cash flow from financing activities?
- What is the all time high annual CFF for Xenon Pharmaceuticals?
- What is Xenon Pharmaceuticals annual CFF year-on-year change?
- What is Xenon Pharmaceuticals quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Xenon Pharmaceuticals?
- What is Xenon Pharmaceuticals TTM cash flow from financing activities?
- What is the all time high TTM CFF for Xenon Pharmaceuticals?
What is Xenon Pharmaceuticals annual cash flow from financing activities?
The current annual CFF of XENE is $353.52 M
What is the all time high annual CFF for Xenon Pharmaceuticals?
Xenon Pharmaceuticals all-time high annual cash flow from financing activities is $447.54 M
What is Xenon Pharmaceuticals annual CFF year-on-year change?
Over the past year, XENE annual cash flow from financing activities has changed by +$75.05 M (+26.95%)
What is Xenon Pharmaceuticals quarterly cash flow from financing activities?
The current quarterly CFF of XENE is $0.00
What is the all time high quarterly CFF for Xenon Pharmaceuticals?
Xenon Pharmaceuticals all-time high quarterly cash flow from financing activities is $324.01 M
What is Xenon Pharmaceuticals TTM cash flow from financing activities?
The current TTM CFF of XENE is $324.01 M
What is the all time high TTM CFF for Xenon Pharmaceuticals?
Xenon Pharmaceuticals all-time high TTM cash flow from financing activities is $606.48 M